Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Real-world persistence and adherence with oral trifluridine/tipiracil or regorafenib in patients with colorectal cancer.
Authors
Fadi S. Braiteh
Comprehensive Cancer Centers of Nevada, Las Vegas, NV
Fadi S. Braiteh , Cynthia J. Girman , Jessica C. Young , Mark D. Danese , Debra E. Irwin , Reza Kazerooni , Tehseen Salimi , Robert Morlock , Robert S. Epstein
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
DOI
10.1200/JCO.2022.40.4_suppl.049
Abstract #
49
Poster Bd #
C3
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
Real-world genomic and treatment landscape in advanced colorectal cancer identifies treatment differences pre- and post-ctDNA genomic profiling.
First Author: Junhua Yu
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Real-world biomarker testing patterns among patients with metastatic colorectal cancer (mCRC) treated with later lines of therapy (LOT) in the United States (US) community oncology setting.
First Author: Arvind Katta
Poster
2023 ASCO Annual Meeting
Effect of colorectal cancer screening on 1-year mortality and medical costs: Real-world evidence from the largest commercial medical claims database in the US.
First Author: Chi Mai Nguyen
Poster
2023 ASCO Annual Meeting
Characterization of MCL-1 in patients with colorectal cancer (CRC): Expression, molecular profiles, and outcomes.
First Author: Pooja Mittal